Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Miltefosine in Children and Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 2-12 years of age, or 18-60 years of age~* Weight greater than 10 kg~* Parasitologic confirmation of cutaneous leishmaniasis~* Normal hepatic and kidney function~Exclusion Criteria:~* Pregnant or lactating women, and women who are planning to conceive during the study or that reject the use of birth control methods.~* Use of drugs with antileishmanial potential during the previous 6 months, including pentavalent antimonials, amphotericin B, miltefosine, and pentamidine~* Mucocutaneous or visceral leishmaniasis~* For female children, menses or other evidence of reproductive maturity

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Miltefosine (Type: EXPERIMENTAL): Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).